Theralase Technologies (CVE:TLT) Stock Price Up 7.8% – Should You Buy?

Theralase Technologies Inc. (CVE:TLT)’s share price traded up 7.8% during mid-day trading on Friday . The company traded as high as C$0.28 and last traded at C$0.28. 298,584 shares changed hands during mid-day trading, an increase of 66% from the average session volume of 180,133 shares. The stock had previously closed at C$0.26.

Theralase Technologies Trading Up 11.8%

The company has a market cap of C$76.70 million, a P/E ratio of -15.83 and a beta of -0.31. The stock’s 50 day moving average is C$0.28 and its 200-day moving average is C$0.23. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.